Introducer's Statement of Intent

LB117

Chairperson: Senator Merv Riepe

Committee: Health and Human Services

Date of Hearing: January 27, 2017

The following constitutes the reasons for this bill and the purposes which are sought to be accomplished thereby:

LB 117, the Investigational Drug Use Act, is more commonly called "Right to Try." The bill allows eligible patients under the Act to be treated with any drug, biological product, or device that has successfully completed Phase 1 of a clinical trial but has not yet been approved for general use by the USFDA and remains in a clinical trial approved by the USFDA.

Principal Introducer: Senator Robert Hilkemann